All photography provided by Jared Chambers


Our Mission

PHIGENIX goal is to establish a novel approach to detecting cancer earlier and identifying the best treatment regime for the patient.  We are currently developing diagnostic tests which may detect abnormalities at the pre-malignant state years before the onset of cancer.  Our therapeutics in development involve blocking the expression of the PAX2 oncogene and the subsequent re-expression of Human Beta Defensin-1 (hBD-1), which is a naturally occurring component of the immune system to fight cancer. Finally, we are developing novel drugs, antibodies and Antibody-drug Conjugates (ADCs) to deactivate PAX2 for cancer treatment and/or prevention.



Other than skin cancer, prostate cancer is the most common cancer among men in the United States. The American Cancer Society’s estimates for prostate cancer in the United States for 2017 are:

About 161,360 new cases of prostate cancer
About 26,730 deaths from prostate cancer

About 1 man in 7 will be diagnosed with prostate cancer during his lifetime.

About 1 man in 39 will die of prostate cancer.



Breast cancer is the most common cancer among women in the United States, except for skin cancers. Currently, the average risk of a woman in the United States developing breast cancer sometime in her life is about 12%. This means there is a 1 in 8 chance she will develop breast cancer. This also means there is a 7 in 8 chance she will never have the disease. The American Cancer Society's estimates for breast cancer in the United States for 2017 are: 

About 252,710 new cases of invasive breast cancer will be diagnosed in women. 
About 63,410 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is non-invasive and is the earliest form of breast cancer). 
About 40,610 women will die from breast cancer.

What We've Achieved

  • Pioneered ground-breaking research in tumor immunity

  • Validated the expression of our biomarker in breast cancer patients

  • Several recent independent studies that support our technology

  • Successfully built a robust patent portfolio to protect our IP

  • Successfully defended the validity of one of our key patents

  • Initiated talks with pharmaceutical and biotech companies for possible licensing